Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elenbecestat - Biogen/Eisai

Drug Profile

Elenbecestat - Biogen/Eisai

Alternative Names: E-2609

Latest Information Update: 27 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eisai Inc
  • Developer Biogen; Eisai Inc; GE Healthcare
  • Class Antidementias; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 13 Sep 2019 Eisai terminates a phase II trial in Alzheimer's disease in USA as a consequence of the discontinuation of MISSION AD1 and MISSION AD2 trials as per the recommendation of the Data Safety Monitoring Board (DSMB) due to unfavorable risk-benefit ratio (PO) (NCT02322021)
  • 13 Sep 2019 Eisai terminates the phase III MISSION AD1 trials in Alzheimer's disease in USA, Argentina, Australia, Austria, Bulgaria, Canada, Czech Republic, France, Germany, Greece, Japan, South Korea, Poland, Portugal, Russia, Slovakia, Spain and United Kingdom
  • 13 Sep 2019 Eisai terminates the phase III MISSION AD2 trials in Alzheimer's disease in USA, Canada, Chile, China, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Japan, South Korea, Mexico, Poland, Portugal, Singapore, Slovakia, South Africa, Spain, Taiwan and United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top